Cytek Biosciences, Inc. (CTKB) stock
CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/309% below fair value
$5.70+0.07 (+1.24%)
Close on Nov 17, 2026Market cap $740.91MP/E –Yield –
Cytek Biosciences pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Cytek Biosciences's pe ratio was 574.0× on Apr 28, 2023, against 728.0× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Apr 28, 2023 | 574.0× | −202.0 |
| 2022 | Oct 31, 2022 | 776.0× | −40.0 |
| 2021 | Dec 31, 2021 | 816.0× | – |
See a number that looks wrong?